by Richard Daverman, PhD
March 13, 2014 -- TaiGen Biotechnology received marketing approval in Taiwan for Taigexyn® (nemonoxacin), a novel antibiotic that is aimed at community-acquired bacterial pneumonia. The approval is the first for TaiGen and for Taigexyn. In April 2013, TaiGen filed a new drug application for China approval of Taigexyn, which remains under review. Two years ago, TaiGen out-licensed China rights for Taigexyn to Zhejiang Medicine Co., which made an $8 million upfront payment. More details....
Stock Symbol: (TWO: 4157)
Help employers find you! Check out all the jobs and post your resume.
